IL6R and COVID-19: However, several randomized controlled trials of the anti-IL-6 receptor (IL-6R) antibody tocilizumab in patients with COVID-19 have shown conflicting results (5–8) and the routine use of tocilizumab in patients with moderate to severe COVID-19 is not generally supported (9).